# FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

> **NCT00683891** · — · COMPLETED · sponsor: **Azur Pharma, Inc**

## Conditions studied

- Weight Gain
- Sialorrhea

## Interventions

- **DRUG:** FazaClo (clozapine, USP) ODT

## Key facts

- **NCT ID:** NCT00683891
- **Lead sponsor:** Azur Pharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683891, "FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00683891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*